BMJ Open

Narrative medicine-based intervention in primary care to reduce polypharmacy: results from the cluster-randomised controlled trial MultiCare AGENDA

Ingmar Schäfer,1 Hanna Kaduszkiewicz, 2 Christine Mellert,3 Christin Löffler,4 Achim Mortsiefer,3 Annette Ernst,1 Carl-Otto Stolzenbach,1 Birgitt Wiese,5 Heinz-Harald Abholz,3 Martin Scherer,1 Hendrik van den Bussche,1 Attila Altiner4

ABSTRACT

Objectives To determine if patient-centred communication leads to a reduction of the number of medications taken without reducing health-related quality of life.

Design Two-arm cluster-randomised controlled trial.

Setting 55 primary care practices in Hamburg, Düsseldorf and Rostock, Germany.

Participants 604 patients 65 to 84 years of age with at least three chronic conditions.

Interventions Within the 12-month intervention, general practitioners (GPs) had three 30 min talks with each of their patients in addition to routine consultations. The first talk aimed at identifying treatment targets and priorities of the patient. During the second talk, the medication taken by the patient was discussed based on a ‘brown bag’ review of all the medications the patient had at home. The third talk served to discuss goal attainment and future treatment targets. GPs in the control group performed care as usual.

Primary outcome measures We assumed that the number of medications taken by the patient would be reduced by 1.5 substances in the intervention group and that the change in the intervention group’s health-related quality of life would not be statistically significantly inferior to the control group.

Results The patients took a mean of 7.0±3.5 medications at baseline and 6.8±3.5 medications at follow-up. There was no difference between treatment and control group in the change of the number of medications taken (0.43; 95% CI −0.07 to 0.93; P=0.094) and no difference in health-related quality of life (0.03; −0.02 to 0.08; P=0.207). The likelihood of receiving a new prescription for analgesics was twice as high in the intervention group compared with the control group (risk ratio, 2.043; P=0.019), but the days spent in hospital were reduced by the intervention (−3.07; −5.25 to −0.89; P=0.006).

Conclusions Intensifying the doctor–patient dialogue and discussing the patient’s agenda and personal needs did not lead to a reduction of medication intake and did not alter health-related quality of life.

Trial registration number ISRCTN46272088; Pre-results.

Strengths and limitations of this study

► The intervention was based on the established concepts of the Chronic Care Model, which was especially designed for the treatment of chronically ill patients, and Narrative Based Medicine, providing a framework for approaching a patient’s problems holistically and possibly helping to reduce medication.

► We carefully designed the study with adequate numbers of recruited patients, with general practitioners (GPs) and patients unaware of study endpoints and the data analysis controlled for relevant confounders, allowing for cluster effects and blinding to group assignment.

► There was a slight patient selection bias regarding gender and certain diagnosis groups, but we found no other baseline differences regarding sociodemographic data and no imbalances regarding medication intake.

► However, we cannot rule out that a higher-than-average percentage of motivated and educated GPs and a higher-than-average percentage of cooperative patients, who had been more satisfied with their primary care than other patients, responded to our invitations for study participation.

► Despite the fact that we monitored the implementation of the intervention by telephone or personal visits to the GPs, we had not been able to observe the consultations with the patients and therefore do not know whether the intervention was implemented per protocol and if the GPs in the control group really conducted care as usual or if they focused more on their patients due to their study participation.

INTRODUCTION

Multimorbidity, that is, the coexistence of two or more chronic conditions in one patient, is a frequent condition in the elderly population. Depending on the definition and operationalisation, its prevalence rate is estimated between 50% and 80% in most studies.12 Many
studies found an association between multimorbidity and adverse patient-related outcomes, for example, higher mortality, limited functioning and reduced health-related quality of life.^{2,5}

Usually, multimorbidity also goes along with polypharmacy, that is, the co-prescription of multiple medications, especially if clinical practice guidelines on all morbidities of a patient are fully applied.^{4,5} Polypharmacy may result in an additional burden to the patient, for example, adverse drug events, fall-related outcomes or hospital admissions.^{6,7} There is some evidence that patients with polypharmacy may benefit from medication withdrawal, especially concerning psychotropic drugs.^{8} However, there are still only few intervention studies addressing the management of multimorbidity,^{9} and the question of how to reduce the number of medications is also still under-researched and unclear.^{10}

Given the high complexity of multimorbidity including the possible interactions of illnesses and medications in multimorbidity patients,^{11,12} there is wide consensus that a patient-centred approach is preferable.^{13,14} Key elements of this approach are shared decision-making between physician and patient, guided by the patient’s central values and priorities as well as coordinated interdisciplinary care, based on a biopsychosocial disease concept.^{14,15}

The Chronic Care Model and Narrative Based Medicine provide a framework for such a patient-centred care. The Chronic Care Model consists of the following elements: (1) joint definition of problems by patient and physician; (2) targeting, goal setting and planning; (3) a continuum of self-management training and support services; and (4) active and sustained follow-up by the professional.^{16,17} Narrative Based Medicine assumes that patient’s narratives of illness can provide a framework for approaching his problems holistically and, thus, may reveal diagnostic and therapeutic options.^{18,19} Narrative Based Medicine can also help in reducing medication.^{20}

The MultiCare AGENDA study investigated the efficacy of a multifaceted intervention based on these concepts. It aimed at improving the doctor–patient dialogue and identifying the patient’s agenda and personal needs. The dialogue included a ‘brown bag’ review. We expected that more patient-centred communication would be able to disclose the main focus of patient care—which would sometimes have implications for medication use. Our primary hypothesis was that patient-centred communication would lead to a reduction in the number of medications taken without affecting health-related quality of life.

These hypotheses were based on the results of several studies showing that longer consultation times with patients were associated with fewer prescriptions and one study showing a better prescribing quality based on the use of 10 categories of medications.^{21} There is growing evidence that the phenomenon of polypharmacy and inappropriate prescribing has primarily been the result of miscommunication (or even non-communication) during the doctor–patient interaction.^{22,23} Therefore, we expected that polypharmacy could be reduced through more intensive communication in terms of dedicating more time on the patient and focusing on the patient’s perspectives without the support of specific medication tools. Despite the fact that there is mixed evidence concerning the question if inappropriate prescribing could be harmful for the patient,^{24} researchers advocate that a reduction of the medication load and adherence to essential medications are of great importance, especially in patients with multimorbidity.^{25}

**METHODS**

**Study design**

Multicare AGENDA was designed as a cluster-randomised controlled trial in general practice. Cluster randomisation was conducted on the general practitioner (GP) practice level. The study intended to evaluate the efficacy of narrative doctor–patient dialogues in patients with multimorbidity. The narrative intervention was tested against care as usual. We conducted the study in three larger German cities (study centres), that is, Hamburg, Düsseldorf and Rostock.

**Setting**

The intervention was GP-led and carried out in GP practices. In each study centre, we randomly selected GPs from the register of the Association of Statutory Health Insurance Physicians and invited them to participate in our study by mail. Additionally, we recruited GPs using Internet and print media advertisements.

**Participants and eligibility criteria**

GPs were eligible for the study if they were willing to participate in the study regardless of randomisation to the intervention or control arm, if they had established an own GP practice for at least 2 years and if they used a practice software that was able to create a list of all their patients based on their ages. We excluded GPs if they had participated in our feasibility study,^{26} or in the MultiCare Cohort Study.^{27} In group practices, only one GP was allowed to participate in the study.

Each participating GP retrieved a list of his patients who were between 65 and 84 years old and had consulted him within the last completed quarter (ie, 3-month period). Up to 25 patients per practice were randomly selected from this list (using random number tables) and checked for exclusion criteria. Only patients with at least three chronic conditions out of a list of 42 diagnosis groups^{28} were included in the study.

Patients were excluded if they were hardly known by the GP (ie, ad hoc consultation, had been a patient of this practice for less than 12 months), if they were not able to consent (eg, dementia) or if they were not able to participate in interviews according to the GP (eg, severe psychiatric illness, deafness, insufficient German language skills). Further exclusion criteria were a life expectancy of 3 months or less according to their GP, residence in a...
nursing home and participation in other scientific trials at the time of recruitment.

If patients were eligible, they were invited by a letter from their GP to participate in the study. If they were interested, the patients consulted their GP to receive information about the study and signed an informed consent form.

Study registration
Rationale and detailed methods of the study can be found in trial registration (http://www.isrctn.com/ISRCTN46272088) and in the published protocol.28

Intervention
We developed and pretested the intervention in a pilot study, which was described in detail in the published protocol.28 The intervention was based on the Chronic Care Model16 17 and Narrative Based Medicine.18 19 GPs allocated to the intervention arm received three training sessions, each lasting for about 4 hours. Each training session was conducted by at least three of the following study team members: AM and COS (experienced GPs), HK (physician) and IS (sociologist). Training topics were how to perform narrative based doctor–patient dialogues reflecting treatment targets and priorities of the patient and how to perform narrative, patient-centred medication reviews as well as goal setting and attainment regarding care and treatments. Simulated patients29 30 were used in the training sessions to practise Narrative Based Medicine.

Within the 12-month intervention time, GPs of the intervention arm held altogether three individual talks with each of their participating patients, which were conducted in addition to routine consultations in the GP's practices at their convenience. Each of these talks was intended to take about 30 min and was based on narratives of the patient prompted by an initial narrative question of the GP.

The first talk carried out after the start of the intervention aimed at identifying the patient’s priorities in life (which could be non-medical) and used this information to carve out treatment targets. This talk was stimulated by the GP’s question asking how the patient had experienced the last 6 months. After the patient’s narrative had ended, the GP could ask for more details about the patient’s topics using the order they had been mentioned. If the talk did not produce topics to discuss, the GP could ask if there had been any changes in the patient’s health status, if the patient had set goals in his life or if something unexpected had happened. Additionally, the GP could ask the patient to describe what he wished to happen (or not to happen) over the next year.

The focus of the second talk, which was conducted within a couple of weeks afterwards, was on the medication taken by the patient based on a ‘brown bag’ review31 where the patient was asked to bring all the medications he had at home into the practice. At the beginning of this talk, the patient was asked to present his medications and to tell if he had taken them, how he had taken them and what he thought about them. GPs should not interrupt in order to allow the patient to present his own views. Then, based on this information, the doctor and the patient should discuss and implement changes, if necessary. Specific medication aids were not used.

The third talk, scheduled 12 months after the first, combined the elements of both previous talks and was used to discuss goal attainment, changes in medication and treatment targets for the future. The initial narrative question and additional supportive questions were the same as in the first talk. During the intervention period, all additional treatments and consultations were permitted.

Comparator
GPs of the control group performed care as usual. At the end of the intervention, they were offered to participate in a similar training as given to the intervention group. This offer had been announced before starting the study to counterbalance the possible lower motivation level of GPs randomly assigned to the control arm. The GPs of the control group received the same remuneration as the GPs of the intervention group.

Primary outcome measures
Our primary outcome measures were the number of medications taken at follow-up (adjusted for the number of medications taken at baseline) and the health-related quality of life at follow-up (adjusted for the health-related quality of life at baseline). Regression coefficients represent the outcome change in the intervention group minus the outcome change in the control group.

We assumed that the number of medications taken by the patient would be reduced as a result of the intervention. A minimum difference of 0.5 medications between both groups was defined as clinically relevant. We assumed that a reduction of medication use would not impair health-related quality of life, that is, we expected that the mean change in health-related quality of life in the intervention group would not be statistically significantly inferior to the mean change in the control group.

Secondary outcome measures
The effects of the intervention on the GP’s knowledge about the medication taken by the patient, patient satisfaction with GP services, patient empowerment as well as healthcare use are reported as outcome changes between baseline and follow-up adjusted for the baseline values and coded as intervention group minus control group.

Data collection and monitoring of GPs
Members of the study team collected the data in personal interviews. GPs were interviewed at their practices and they were able to validate their answers in the patient medical records. Patient interviews were conducted at the patients’ homes. Baseline data were collected between October 2011 and June 2012 and follow-up data between November 2012 and July 2013. Data collection of the
intervention group was performed before the intervention started (baseline) and after it finished (follow-up). Baseline assessments of the control group were conducted after patient recruitment and follow-up assessments 14 months after the baseline interview. During the intervention, each GP was contacted at least twice by telephone or personally visited by a member of the study team (COS) in order to monitor the implementation of the intervention and to get information about potential harms for the patients.

We used data on the patients’ age and gender from GP charts and data on education, type of household, patient satisfaction, empowerment and healthcare use from patient interviews. The highest level of attained education was described according to the international Comparative Analysis of Social Mobility in Industrial Nations questionnaire (CASMIN) classification in three groups: (1) inadequately completed general education, general elementary education or basic vocational qualification; (2) intermediate qualification or A level equivalent; and (3) lower or higher tertiary education. Patient satisfaction with GP services was measured by the EURO- pean task force on Patient Evaluations of general Practice care (EUREP) questionnaire, which was scored in the subscales ‘clinical performance’ and ‘organisation of care’ ranging between 0 and 4 points each. Patient empowerment was assessed with the Health Care Empowerment Questionnaire (HCEQ). The scores in the dimensions ‘involvement in interactions’ and ‘involvement in decisions’ were determined by the cross-product between motivation for control and perception of control in each item and ranged between 4 and 64 points and 3 and 48 points, respectively. In the EUROPEP and the HCEQ scores, higher values indicated a higher amount of patient satisfaction and empowerment, respectively.

Data on healthcare use were collected using a short form of the Leipzig Supply and Cost Instrument covering the number of contacts with outpatient physicians as well as physical, occupational and speech therapy units during the last 3 months. It also includes number and length of hospital stays during the last 6 months. Additionally, the patient interviews contained the Geriatric Depression Scale with a total score range between 0 and 15 points and the Geriatric Depression Scale with a total score range between 0 and 15 points. This list was compiled by an interdisciplinary expert group based on the criteria of prevalence and chronicity.

Sample size
We expected a mean reduction of 1.5 medications per patient in the intervention group, a SD of 3.5 medications, an intraclass correlation coefficient of $\rho=0.14$ and a dropout rate of 20%. We defined an $\alpha=0.025$ in order to adjust for multiple testing and a power of 80%. Based on the assumption of 10 recruited patients per practice, a minimum sample size of 594 patients was needed for the first primary outcome. The rationale for our assumptions can be found in the published protocol.

Concerning the endpoint health-related quality of life, we expected no differences between intervention and control group. With this in mind, we assumed that the mean score of the intervention group at the end of the intervention would be at most half a SD less than the mean score of the control group and we estimated the SD as 0.30. Thus, a minimum sample size of 362 patients was needed to analyse the second primary outcome.

Randomisation
GP practices were randomised to conduct the intervention or to continue with care as usual (control). Randomisation was carried out after patient recruitment and baseline interviews with recruited patients had been completed. Block randomisation was used to provide comparable numbers of patients in the treatment and the control group. The randomisation was stratified by the number of patients recruited per practice (categories: ≤10, 10–25, 26–50, >50 patients) using a block size of 4 and a ratio of 1:1.

Blinding and allocation concealment
The intervention was led by GPs; therefore, blinding study GPs and their patients was not possible. However, based on the contents of the intervention, the GPs could speculate about the endpoints, but they were not informed by the study team of study hypotheses and primary outcome measures. Assessors who performed...
GP and patient interviews could not effectively be blinded because they communicated with GPs and practice personnel. For that reason, we cannot rule out that they had received information about the group assignment of the practice. Randomisation was conducted by BW (Hanover) blinded to names and addresses of the GPs. The statistical analysis was performed by IS (Hamburg) blinded to group assignment of the GPs (ie, intervention or control group).

Statistical methods

Descriptive data were presented as means and SD and as percentages, respectively. We compared the treatment and control group with t-tests in case of continuous variables and \( \chi^2 \) tests in case of categorical variables. Changes in medication between baseline and follow-up were described for the treatment and control group and analysed by \( \chi^2 \) tests. These analyses were adjusted for familywise error rate in multiple testing using the Benjamini-Hochberg procedure.41

We analysed the number of medications taken by the patients at follow-up, the GP’s knowledge of the patients’ medication, the patient satisfaction with GP services, the patient empowerment as well as the healthcare use (response variables) by multilevel mixed-effects linear regression allowing for random effects at the study centre and GP practice within study centre level. The health-related quality of life at follow-up was not normally distributed. We therefore analysed this response variable using multilevel mixed-effects ordinal logistic regression allowing for random effects at the study centre and GP practice within study centre level. The analyses of all of these response variables were baseline adjusted and controlled for the time between baseline and follow-up. Group assignment in our primary analyses was based on intention to treat, that is, based on the intended group assignment regardless of fulfilling the protocol.

Sensitivity analyses were conducted with the group assignments ‘as treated’, that is, based on the treatment the patients received de facto, and ‘per protocol’, that is, including only practices fulfilling the protocol regarding the intended group assignment and excluding practices that did not. We also conducted additional exploratory analyses adjusted for age, gender, type of household, education, depression and chronic diseases in different statistical models.

Furthermore, the change of medication profiles over the study period was analysed using multilevel mixed-effects logistic regression allowing for random effects at the study centre and GP practice within study centre level and controlled for age, gender and time between baseline and follow-up. To support the discussion, ORs from these analyses were recalculated into risk ratios as risk ratios do not depend on the prevalence of a condition and are therefore easier to interpret.42

Due to the two primary endpoints, Bonferroni correction was applied to our analyses of the primary outcomes to adjust for multiple comparisons, that is, we defined an \( \alpha \)-level of 2.5\% (ie, \( P \leq 0.025 \)) as statistically significant. For all additional analyses, we defined an \( \alpha \)-level of 5\% (ie, \( P \leq 0.05 \)) as statistically significant. Ordinal logistic regression analyses were performed using Stata V.14.2. All other statistical tests were conducted using Stata V.12.1.

Patient involvement

In order to understand the patients’ health problems and healthcare needs, we conducted qualitative in-depth interviews with 19 patients during the development of the intervention.43 44 Additionally, we conducted standardised telephone interviews with the participating patients during our feasibility study and analysed transcripts of the patients’ consultations with their GPs during our pilot study.26 The patient perspective obtained from these data was used in the study design, formulation of hypotheses and interpretation of study results.

RESULTS

Participant flow

Sampling and response rates are shown in figure 1. We checked 4028 patients for inclusion and exclusion criteria. A total of 1358 patients were eligible for study participation and contacted for informed consent. Moreover, 663 (48.8\%) of these patients agreed to participate in our study. However, before the baseline assessment, 13 patients dropped out of the study because they had either died, their health status had severely deteriorated, they had changed their GP or they had participated in other scientific studies without their GPs’ knowledge.

A total of 650 patients from 55 practices were randomised to the treatment and control group. All these patients completed the baseline assessment. From the control and the intervention group, 6.2\% and 8.0\%, respectively, were lost to follow-up. All in all, 305 patients from 27 practices in the control group and 299 from 28 practices in the intervention group participated in the study and completed the follow-up assessment.

Baseline and follow-up data

We found no differences between the intervention and control group regarding the characteristics of GPs and practices (cf. table 1). On average, the intervention group had a 65 days longer period between baseline and follow-up assessment. Additionally, the control group had a significantly higher proportion of female patients than the intervention group (58.7\% vs 50.5\%), but there were no differences in age, type of household and education. The data from the depression screening, and number of chronic conditions were also similar between the groups (cf. table 2).

Regarding the primary and secondary outcome measures at baseline and follow-up, there were no differences between the groups except for slightly better baseline values in the intervention group regarding the EUROPEP—Organisation of Care subscale (3.2 points vs 3.0 points) and the GP’s knowledge of the patients’
medication (66.6% vs 61.1%) (cf. table 3). The medications taken differed only regarding more patients in the control group using active ingredients classified by the level 2 ATC codes ‘A11—vitamins’ (11.5% vs 6.4%) and ‘M09—other musculo-skeletal system’ (1.3% vs 0) (cf. table 4).

**Effects on primary outcomes**

The effect of our intervention on the outcomes can be found in table 5. There was no statistically significant difference between the treatment and the control group in the change of the number of medications. The intra-cluster correlation coefficient (ICC) of the number of medications was 0.00 (95% CI 0.00 to 0.00) on the study centre level and 0.03 (0.00 to 0.13) on the practice level. Sensitivity analyses ‘as treated’ and ‘per protocol’ showed similar results.

Our additional exploratory analyses revealed that the change in the number of medications taken by the patient remained statistically non-significant when step-wise adjusted for age, gender, type of household, education, Geriatric Depression Scale score and 46 chronic diseases. Regarding health-related quality of life, there was no significant difference between the treatment and control groups. The ICC of health-related quality of life was 0.01 (0.00–0.13) on the study centre level and 0.03 (0.01–0.17) on the practice level.

**Figure 1** Sampling and response rates of patients. ‘Multimorbidity’ is defined as at least 3 out of 42 ICD-10-based diagnosis groups. ICD, International Classification of Diseases.
There were no effects of the intervention on patient satisfaction, patient empowerment and the GP’s knowledge about the medication taken by the patient. However, healthcare use developed differently between groups. Compared with the control group, the amount of contacts with GPs increased in the intervention group (+0.51 contacts in the last 3 months), whereas the amount of physical, occupational or speech therapy (−1.38 units in the last 3 months) and the days spent in hospital (−3.07 days in the last 6 months) decreased (cf. table 5).

**Potential harms**

Figure 2 shows a comparison between the treatment and the control group regarding the change of medication profiles during the study period. There was a significant increase in the frequency of treatment with active ingredients in the ATC groups C08 (ie, calcium channel blockers), M01 (ie, anti-inflammatory and antirheumatic agents), N02 (ie, analgesics) and N06 (ie, psychoanaleptics) in the intervention group compared with the control group. After adjustment for age, gender and the time between baseline and follow-up, most of these differences disappeared. However, the difference in newly prescribed analgesics remained statistically significant after adjustment for these variables, showing that the likelihood of receiving a new prescription for analgesics was twice as high in the intervention group compared with the control group (risk ratio, 2.043; P=0.019). Beyond this finding, which could be interpreted as a negative side effect of the study, the GPs reported no adverse events of the intervention.

**Effects on secondary outcomes**

Table 1 Characteristics of general practitioners (GPs) and practices

|                  | Care as usual (n=27) | Intervention (n=28) | P     |
|------------------|----------------------|---------------------|-------|
| **Age at baseline: mean±SD** | 50.8±6.9 years | 48.2±5.0 years | 0.117 |
| **Gender**       |                      |                     |       |
| Female           | 51.9 %               | 42.9 %              | 0.504 |
| Male             | 48.2 %               | 57.1 %              |       |
| **Specialty of GP** |                     |                     |       |
| Family medicine  | 74.1 %               | 64.3 %              | 0.432 |
| Internal medicine| 18.5 %               | 39.3 %              | 0.090 |
| **No specialty** | 7.4 %                | 6.4 %               | 0.531 |
| **No of physicians working in practice** | 2.0±1.2 | 2.1±0.9 | 0.903 |
| **No of patients treated in practice per quarter** | 1457±817 | 1404±673 | 0.792 |

n, number of observations.

Table 2 Patients’ sociodemographic data, health status and time between baseline and follow-up

|                  | Care as usual (n=305) | Intervention (n=299) | P     |
|------------------|-----------------------|----------------------|-------|
| **Age at baseline: mean±SD** | 73.5±5.0 years | 73.3±4.8 years | 0.679 |
| **Gender**       |                      |                     |       |
| Female           | 58.7 %               | 50.5 %              | 0.043 |
| Male             | 41.3 %               | 49.5 %              |       |
| **Type of household** |                     |                     |       |
| Living in private home alone | 40.0% | 30.4% | 0.082 |
| Living in private home with spouse | 55.1% | 64.6% |       |
| Living in private home with family members | 1.3% | 3.0% |       |
| Living in private home with other persons | 0.3% | 0.3% |       |
| Living in assisted living facility | 2.6% | 1.3% |       |
| Living in retirement home | 0.7% | 0.3% |       |
| **Education (CASMIN classification)** |             |                     |       |
| Low              | 54.4 %               | 56.2 %              | 0.479 |
| Medium           | 29.8 %               | 25.8 %              |       |
| High             | 15.7 %               | 18.1 %              |       |
| **No of chronic diseases (based on a list of 46): mean±SD** | 8.4±3.5 | 8.7±4.3 | 0.335 |
| **Geriatric Depression Scale score: mean±SD** | 2.2±2.7 | 2.1±2.4 | 0.566 |
| **Time between baseline and follow-up: mean±SD** | 376±27 days | 441±66 days | <0.001 |

CASMIN, Comparative Analysis of Social Mobility in Industrial Nations questionnaire; n, number of observations.

**DISCUSSION**

**Principal findings**

MultiCare AGENDA was conducted to examine if additional GP consultations structured by the Chronic Care Model could improve medication management and thereby enhance the quality of medication-related care for older patients. The study was designed as a pragmatic, multicenter randomized controlled trial with a focus on participants’ and physicians’ perspectives. The primary outcome was the change in medication profiles and secondary outcomes were patient satisfaction, patient empowerment and GPs’ knowledge about the medication taken by the patient. The study showed that the intervention group had a significantly higher amount of contacts with GPs (+0.51 contacts in the last 3 months), whereas the amount of physical, occupational or speech therapy (−1.38 units in the last 3 months) and the days spent in hospital (−3.07 days in the last 6 months) decreased (cf. table 5).

**Potential harms**

Figure 2 shows a comparison between the treatment and the control group regarding the change of medication profiles during the study period. There was a significant increase in the frequency of treatment with active ingredients in the ATC groups C08 (ie, calcium channel blockers), M01 (ie, anti-inflammatory and antirheumatic agents), N02 (ie, analgesics) and N06 (ie, psychoanaleptics) in the intervention group compared with the control group. After adjustment for age, gender and the time between baseline and follow-up, most of these differences disappeared. However, the difference in newly prescribed analgesics remained statistically significant after adjustment for these variables, showing that the likelihood of receiving a new prescription for analgesics was twice as high in the intervention group compared with the control group (risk ratio, 2.043; P=0.019). Beyond this finding, which could be interpreted as a negative side effect of the study, the GPs reported no adverse events of the intervention.
Model and Narrative Based Medicine could reduce polypharmacy without affecting the patients’ health-related quality of life. In our study, this approach did not prove to be effective. This might be attributed to patient-related or GP-related barriers to medication discontinuation. For example, a systematic review of 21 articles, published after the beginning of our study, described patient-reported barriers to deprescribing due to patient disagreement with the appropriateness of cessation, absence of a planned process for cessation, negative influences on the patient to cease the medication and the patient’s fear of cessation. Furthermore, a systematic review of additional 21 studies identified prescriber-related barriers, such as missing problem awareness, inertia combined with a low perceived value of medication discontinuation, provider’s low self-efficacy in regard to altering prescribing patterns and problems with the feasibility of altering the medication in routine care environments.

The lack of efficacy of our study might also stem from the fact that the participating GPs were unaware of study endpoints and polypharmacy was not explicitly addressed. The additional consultations in the intervention group

|                          | Care as usual (n=305) | Intervention (n=299) | P       |
|--------------------------|----------------------|----------------------|---------|
| Medications taken by the patient: mean±SD |                      |                      |         |
| At baseline              | 7.0±3.5 (n=304)      | 7.1±3.5              | 0.715   |
| At follow-up             | 6.8±3.5 (n=304)      | 7.3±3.4              | 0.086   |
| EQ-5D score (value set UK): mean±SD |                      |                      |         |
| At baseline              | 0.69±0.28 (n=302)    | 0.67±0.30            | 0.455   |
| At follow-up             | 0.70±0.28 (n=303)    | 0.68±0.32 (n=298)    | 0.473   |
| EUROPEP—Clinical Performance score: mean±SD |                      |                      |         |
| At baseline              | 3.1±0.72 (n=284)     | 3.1±0.69 (n=277)     | 0.353   |
| At follow-up             | 2.9±0.72 (n=268)     | 3.0±0.71 (n=260)     | 0.465   |
| EUROPEP—Organisation of Care score: mean±SD |                      |                      |         |
| At baseline              | 3.0±0.71 (n=267)     | 3.2±0.56 (n=244)     | 0.003   |
| At follow-up             | 3.0±0.63 (n=263)     | 3.1±0.55 (n=240)     | 0.483   |
| HCEQ—Involvement in Interactions score: mean±SD |                      |                      |         |
| At baseline              | 36.1±9.3 (n=303)     | 37.1±9.2 (n=294)     | 0.176   |
| At follow-up             | 37.6±9.2 (n=301)     | 37.4±9.0 (n=292)     | 0.821   |
| HCEQ—Involvement in Decisions score: mean±SD |                      |                      |         |
| At baseline              | 24.3±8.1             | 23.9±8.2             | 0.542   |
| At follow-up             | 24.5±8.3 (n=302)     | 23.3±8.5 (n=298)     | 0.065   |
| GP’s knowledge of active ingredients taken (%): mean±SD |                      |                      |         |
| At baseline              | 61.1±26.2 (n=304)    | 66.6±25.6 (n=298)    | 0.009   |
| At follow-up             | 64.2±27.2 (n=302)    | 66.4±28.0            | 0.338   |
| Contacts with GPs: mean±SD |                      |                      |         |
| At baseline              | 2.6±3.9              | 2.3±2.0              | 0.153   |
| At follow-up             | 2.1±2.3              | 2.4±2.1              | 0.081   |
| Contacts with other outpatient physicians: mean±SD |                      |                      |         |
| At baseline              | 2.2±2.4              | 2.1±2.3              | 0.665   |
| At follow-up             | 2.0±2.6              | 2.2±3.2              | 0.539   |
| Physical, occupational or speech therapy units: mean±SD |                      |                      |         |
| At baseline              | 1.6±4.7              | 1.8±5.0              | 0.669   |
| At follow-up             | 3.0±8.0              | 2.3±5.7              | 0.205   |
| Days spent in hospital: mean±SD |                      |                      |         |
| At baseline              | 2.0±6.9              | 2.6±8.7              | 0.412   |
| At follow-up             | 3.5±12.1             | 2.6±8.3 (n=298)      | 0.258   |

EUROPEP, EUROpean task force on Patient Evaluations of general Practice care questionnaire; EQ-5D, EuroQol group 5 Dimensions questionnaire; GP, general practitioner; HCEQ, Health Care Empowerment Questionnaire; n, number of observations.
| ATC  | Medication                          | Care as usual (n=304) | Intervention (n=299) | P*     |
|------|-------------------------------------|-----------------------|----------------------|--------|
| C09  | Angiotensin inhibitor               | 68.8%                 | 65.2%                | 0.356  |
| C07  | Beta-receptor blocker               | 48.0%                 | 55.2%                | 0.079  |
| B01  | Antithrombotical agents             | 51.0%                 | 50.8%                | 0.970  |
| C10  | Antilipemics                        | 47.4%                 | 42.1%                | 0.197  |
| A02  | Ulcer therapeutics                  | 28.0%                 | 32.8%                | 0.198  |
| C03  | Diuretics                           | 25.7%                 | 25.8%                | 0.979  |
| A10  | Antidiabetics                       | 21.1%                 | 23.4%                | 0.486  |
| H03  | Thyroid therapeutics                | 23.0%                 | 21.1%                | 0.562  |
| M01  | Antiphlogistics/anti-inflammatory    | 21.7%                 | 21.4%                | 0.927  |
| N02  | Analgesics                          | 20.7%                 | 22.1%                | 0.686  |
| C08  | Calcium antagonists                 | 22.4%                 | 19.1%                | 0.317  |
| R03  | Antiasthma medication               | 16.1%                 | 14.4%                | 0.553  |
| C01  | Cardiac therapeutics                | 12.5%                 | 16.7%                | 0.142  |
| N06  | Psychoanaleptics                    | 14.8%                 | 14.1%                | 0.792  |
| G04  | Urological drugs                    | 11.8%                 | 14.7%                | 0.298  |
| S01  | Ophthalmic drugs                    | 13.5%                 | 12.4%                | 0.684  |
| M04  | Gout agents                         | 9.9%                  | 9.0%                 | 0.725  |
| N05  | Psycholeptics                       | 9.5%                  | 9.0%                 | 0.829  |
| A11  | Vitamins                            | 11.5%                 | 6.4%                 | 0.027  |
| A12  | Minerals                            | 10.9%                 | 7.0%                 | 0.099  |
| H02  | Corticosteroids (systemic)          | 4.6%                  | 5.7%                 | 0.548  |
| N04  | Anti-parkinson drugs                | 3.6%                  | 6.7%                 | 0.088  |
| A06  | Laxatives                           | 5.3%                  | 4.7%                 | 0.743  |
| R05  | Cough and cold preparations         | 4.9%                  | 5.0%                 | 0.963  |
| N03  | Antiepileptics                      | 5.6%                  | 3.3%                 | 0.182  |
| A03  | Spasmolytics                        | 4.3%                  | 4.0%                 | 0.871  |
| M02  | Anti-inflammatory agents (topical)  | 3.0%                  | 4.4%                 | 0.364  |
| C02  | Antihypertensives                   | 3.0%                  | 4.4%                 | 0.364  |
| M05  | Osteoporosis agents                 | 2.6%                  | 4.0%                 | 0.343  |
| G03  | Sexual hormones                     | 2.6%                  | 3.7%                 | 0.462  |
| B03  | Antinaemic combinations             | 3.6%                  | 2.3%                 | 0.357  |
| R01  | Rhinological drugs                  | 2.3%                  | 3.7%                 | 0.321  |
| J01  | Antibiotics                         | 2.6%                  | 2.7%                 | 0.973  |
| N07  | Antivertiginous and addiction       | 3.0%                  | 2.3%                 | 0.636  |
| D07  | Corticosteroids (dermatological)    | 2.3%                  | 2.3%                 | 0.975  |
| R06  | Antihistamines                      | 2.6%                  | 1.7%                 | 0.417  |
| C05  | Vasoprotectives                     | 3.0%                  | 1.0%                 | 0.085  |
| L02  | Hormone antagonists                 | 1.3%                  | 2.0%                 | 0.507  |
| A07  | Antidiarrheals                      | 1.6%                  | 1.3%                 | 0.756  |
| R02  | Throat and pharynx therapeutics     | 0.7%                  | 2.0%                 | 0.148  |
| D01  | Antifungals (topical)               | 1.3%                  | 1.3%                 | 0.981  |
| D11  | Other dermatological preparations   | 1.3%                  | 1.3%                 | 0.981  |
| L04  | Immunosuppressants                  | 0.7%                  | 1.0%                 | 0.640  |
| M03  | Muscle relaxants                    | 1.0%                  | 0.3%                 | 0.324  |
| M09  | Other musculo-skeletal system       | 1.3%                  | 0%                   | 0.047  |

*Statistically significant change (P<0.05 Benjamini-Hochberg adjusted for 45 statistical tests).

ATC, Anatomical Therapeutic Chemical classification system.
Table 5  Effect of the intervention on primary and secondary outcomes: results from multilevel mixed-effects linear regression* and multilevel mixed-effects ordinal logistic regression† analyses (nstudy centres=3; npractices=55; npatients=602)

|                          | Model 1 |       |       | Model 2 |       |       | Model 3 |       |
|--------------------------|---------|-------|-------|---------|-------|-------|---------|-------|
|                          | β       | CI    | P     | β       | CI    | P     | β       | CI    | P     |
| **Primary outcomes**     |         |       |       |         |       |       |         |       |       |
| No of medications (intention to treat) | 0.43    | −0.07 to 0.93 | 0.094 | 0.53‡  | 0.01 to 1.06 | 0.046 | 0.43‡  | −0.07 to 0.93 | 0.095 |
| No of medications (as treated) | 0.45    | −0.05 to 0.95 | 0.079 |         |       |       |         |       |       |
| No of medications (per protocol) | 0.48    | −0.03 to 1.00 | 0.067 |         |       |       |         |       |       |
| EQ-5D value set UK (intention to treat) | 0.34    | −0.05 to 0.74 | 0.091 |         |       |       |         |       |       |
| **Secondary outcomes**   |         |       |       |         |       |       |         |       |       |
| EUROPEP—Clinical Performance score | 0.01    | −0.11 to 0.13 | 0.916 |         |       |       |         |       |       |
| EUROPEP—Organisation of Care score | −0.05   | −0.18 to 0.08 | 0.416 |         |       |       |         |       |       |
| HCEQ—Involvement in Interactions score | −0.33   | −1.82 to 1.15 | 0.662 |         |       |       |         |       |       |
| HCEQ—Involvement in Decisions score | −0.29   | −1.70 to 1.12 | 0.685 |         |       |       |         |       |       |
| GP’s knowledge of the patients’ medication (%) | 1.17    | −6.76 to 9.10 | 0.772 |         |       |       |         |       |       |
| Contacts with GPs         | 0.51    | 0.12 to 0.90 | 0.010 |         |       |       |         |       |       |
| Contacts with other outpatient physicians | 0.43    | −0.13 to 0.99 | 0.134 |         |       |       |         |       |       |
| Physical, occupational or speech therapy units | −1.38   | −2.73 to −0.04 | 0.044 |         |       |       |         |       |       |
| Days spent in hospital    | −3.07   | −5.25 to −0.89 | 0.006 |         |       |       |         |       |       |

Model 1: baseline-adjusted, controlled for age, gender and time between baseline and follow-up and allowing for random effects of study centres and GP practices within study centres; Model 2: Model 1 additionally controlled for household type and education; Model 3: Model 2 additionally controlled for Geriatric Depression Scale score and 46 chronic diseases.

*Analyses of primary outcome ‘number of medications’ and secondary outcomes.
†Analyses of primary outcome ‘EQ-5D value set UK’.
‡Statistically significant increase in model fit compared with nested model (results from likelihood ratio test).
EUROPER EUROpean task force on Patient Evaluations of general Practice care questionnaire; EQ-5D, EuroQol group 5 Dimensions questionnaire; GP, general practitioner; HCEQ, Health Care Empowerment Questionnaire.
resulted in an increase of the number of analgesics. Our intervention might therefore have supported the identification and treatment of unrecognised health problems, such as chronic pain, which are sometimes difficult to detect in routine care. Additionally, the intervention resulted in a reduction of the physical, occupational and speech therapy units and the days spent in hospital. These findings can be interpreted as an improvement in healthcare due to a more intensive GP care and knowledge of the problems of the patient.

However, it has to be taken into account that our study has shown no change in the intervention group’s health-related quality of life compared with the control group. Prescribing a high number of medications can have many reasons, including health status and socio-demographic factors, such as age, race or education. An additional important factor is the use of healthcare, including the number of consultations in primary care, which had increased as part of the intervention in our study. For this reason, our intervention might have contributed to an oversupply of medications in the multimorbid population.

**Comparison with the literature**

Other approaches aiming at reducing polypharmacy are more specifically related to the outcome than the

| Drug Class | Loss after baseline | Gain at follow-up |
|------------|---------------------|-------------------|
| C09 Angiotensin inhibitor | O | X |
| C07 Beta-receptor blocker | X | O |
| R01 Antithrombotical agents | O | X |
| C10 Antilipemics | O | X |
| A02 Ulcer therapeutics | O | X |
| C03 Diuretics | O | X |
| A10 Antidiabetics | X | O |
| H03 Thyroids therapeutics | X | O |
| M01 Antiphlogistics/anti-inflammatory | O | X |
| N02 Analgesics | X | O |
| B02 Calcium antagonists | O | X |
| R03 Anti-asthma medication | O | X |
| C01 Cardiac therapeutics | O | X |
| N06 Psychoneutrics | O | X |
| G04 Urological drugs | O | X |
| M04 Gout agents | O | X |
| N05 Psychotics | O | X |
| A11 Vitamins | O | X |
| A12 Minerals | O | X |
| A06 Laxatives | O | X |
| H02 Corticosteroids (systemic) | O | X |
| N04 Anti parkinson drugs | O | X |
| R05 Cough and cold preparations | O | X |
| N03 Antiepiletics | O | X |
| A03 Spasmolytics | O | X |
| M02 Anti-inflammatory agents (topical) | O | X |
| C02 Antihypertensives | O | X |
| M05 Osteoporosis agents | O | X |
| G03 Sexual hormones | O | X |
| B03 Antianemic combinations | O | X |
| R01 Rhinologic drugs | O | X |
| J01 Antibiotics | O | X |
| N07 Anti vertiginous and addiction | O | X |
| D07 Corticosteroids (dermatological) | O | X |
| R06 Antihistamines | O | X |
| C05 Vasoprotectives | O | X |
| L02 Hormone antagonists | O | X |
| A07 Antidiarrheals | O | X |
| R02 Throat and pharynx therapeutics | O | X |
| D01 Antifungals (topical) | O | X |
| D11 Other dermatological preparations | O | X |
| L04 Immunosuppressants | O | X |
| M03 Muscle relaxants | O | X |
| M09 Other musculo-skeletal system | O | X |

**Figure 2** Changes of medication in treatment and control group between baseline and follow-up. Example reading of C09 angiotensin inhibitor: 5.4% of intervention group patients and 3.3% of control group patients took an angiotensin inhibitor at baseline but had discontinued this medication at follow-up. At the same time, 3.3% of control group patients and 4.4% of intervention group patients did not have an angiotensin inhibitor at baseline but had obtained this medication at follow-up. *Statistically significant difference (P≤0.05 Benjamini-Hochberg adjusted for 45 statistical tests). O, change in intervention group; X, change in control group.
approach of our study, for example, withdrawal of specific classes of medications, medication reviews by physicians or pharmacists with the explicit aim of deprescribing, audit and feedback, educational approaches and interventions based on multidisciplinary teams. A systematic review of 2012 identified four pharmacist-based, four physician-based and two multidisciplinary-based interventions to reduce polypharmacy. Eight of these 10 studies showed a significant reduction in the number of medications. For example, in a study on 160 residents of a nursing home, who used 16.6 medications on average, a physician medication review was conducted based on updated Beers Criteria and the Epocrates online drug–drug interaction programme. This intervention resulted in a mean reduction of 1.1 medications per patient.

These results were confirmed by a more recent systematic review of 2016 on 116 deprescribing trials. The study concluded that deprescribing was feasible but difficult to implement. In the systematic review, mortality was significantly reduced only in randomised studies of patient-specific interventions. Therefore, the authors stressed the importance of an individualised approach on the reduction of polypharmacy. However, in another systematic review, the authors concluded that it was still unclear how best to organise and implement strategies in order to reduce inappropriate polypharmacy or have an impact on clinically relevant endpoints in patients with polypharmacy.

Strengths and weaknesses

Strengths of our study are related to the study design with adequate numbers of recruited patients, the GPs and patients being unaware of study endpoints and the data analysis controlled for relevant confounders, allowing for cluster effects and blinding to group assignment. However, our study results do not necessarily provide evidence against the effectiveness of a narrative chronic care intervention to reduce polypharmacy in primary care. There are three factors related to the study design that may also account for the lack of effectiveness.

First, we trained and monitored the GPs in the intervention group to conduct the narrative-based intervention and we instructed the GPs in the control group to continue with care as usual. Despite the fact that we monitored the implementation of the intervention by telephone or personal visits to the GPs, we had no possibility to observe the consultations with the patients. For this reason, we do not know if the intervention had been implemented per protocol. Furthermore, we also do not know if the GPs from the control group really had conducted care as usual or whether they had focused more on their patients due to their study participation.

Second, there might be a selection bias in our GP population if a higher-than-average percentage of motivated and educated GPs responded to our invitations for study participation. This bias might even have increased because we had randomly selected GPs from the official physician register in statutory healthcare and through Internet and print media advertisements.

Thirdly, the missing efficacy of our study might also result from the fact that our study did not explicitly address oversupply and misuse of certain classes of medications, but aimed at identifying and addressing unmet needs of patients as well. This problem has been discussed in literature. For example, in a systematic review of the literature, Hajjar et al stated that polypharmacy might not be reduced if intervention studies simultaneously addressed overuse and underuse of medications as both effects might even out each other. Regarding the secondary outcomes, it needs to be noted that healthcare costs could not be quantified in Euros in the short form of the Leipzig Supply and Cost Instrument, but instead are expressed as use of healthcare providers.

There are also some limitations related to the representativeness of the study. The population was recruited among patients with multimorbidity who visited their GPs during the study period. Thus, non-users of general practice services were not included. Furthermore, we obtained a response rate of 48.8%, which means that more than half of the eligible population refused to participate in the study. However, on average, we recruited two patients more per practice than expected and the sample included 56 patients more than planned. As with most population-based healthcare research, selection bias towards cooperative patients who may have been more satisfied with their primary care than other patients cannot be excluded. Besides a slight patient selection bias regarding gender and certain diagnosis groups, we found no other baseline differences regarding sociodemographic data and no bias regarding medication intake.

CONCLUSIONS

This is the first cluster-randomised controlled trial investigating the effects of a multifaceted intervention based on the Chronic Care Model and Narrative Based Medicine on the number of medications taken and health-related quality of life. Intensifying the doctor–patient dialogue and discussing the patient’s agenda and personal needs did not lead to a reduction of medication intake nor did it alter health-related quality of life. Exploratory analyses show that the additional consultations in our intervention group probably have not been without any effect, but may have resulted in an increase of the medication load, especially regarding analgesics. Future interventions addressing both oversupply and undersupply of medications should therefore be accompanied by measures preventing an inappropriate prescription of medications.

Contributors HK, AA, HHA and HvdB conceived and designed the study. IS, BW, CM, CL, AM, AE, C-OS and MS significantly contributed to the final design of the study. BW randomised the GP practices and prepared the data for analysis. IS analysed the data. IS and HK drafted the manuscript. All authors commented on the draft and approved the final version of the manuscript.

Funding This study was funded by the German Federal Ministry of Education and Research (grant nos. 01ET1006A, 01ET1006H, 01ET1006I and 01ET1006K).
Competing interests None declared.

Patient consent Detail has been removed from this case description/these case descriptions to ensure anonymity. The editors and reviewers have seen the detailed information available and are satisfied that the information backs up the case the authors are making.

Ethics approval The study was approved by the Ethics Committee of the Medical Association of Hamburg in July 2011 (Approval No. PV3788).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Data are not available for other researchers.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES
1. Violan C, Fougnet-Boreu Q, Flores-Mateo G, et al. Prevalence, patterns and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One 2014;9:e102146.
2. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011;10:430–9.
3. Gilsen R, Hoeymans N, Schellevis FG, et al. Causes and consequences of comorbidity: a review. J Clin Epidemiol 2001;54:661–74.
4. Marengoni A, Onder G. Guidelines, polypharmacy, and drug–drug interactions in patients with multimorbidity. BMJ 2015;350:h1059.
5. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases. JAMA 2005;294:716–24.
6. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. J Intern Med 2015;175:287–334.
7. Fried TR, O'Leary J, Towlie V, et al. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc 2014;62:2261–72.
8. Iyer S, Nagarathan V, McLachlan AJ, et al. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging 2008;25:1021–31.
9. Smith SM, Wallace E, O'Dowd T, et al. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. Cochrane Database Syst Rev 2016;14:CD006650.
10. Cooper JA, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. BMJ Open 2015;5:e009235.
11. van den Bussche H, Koller D, Kolonko T, et al. Which chronic diseases and disease combinations are specific to multimorbidity in the elderly? Results of a claims data based cross-sectional study in Germany. BMC Public Health 2011;11:101.
12. Schäfer I, Kaduszkiewicz H, Wagner HO, et al. Reducing complexity: a visualisation of multimorbidity by combining disease clusters and triads. BMC Public Health 2014;14:1265.
13. Boyd CM, Lucas GM. Patient-centered care for people living with multimorbidity. Curr Opin HIV AIDS 2014;9:419–27.
14. Boyd CM, Reider L, Frey K, et al. The effects of guided care on the perceived quality of health care for multi-morbid older persons: 18-month outcomes from a cluster-randomized controlled trial. J Gen Intern Med 2010;25:235–42.
15. Scholl I, Zill JM, Härtner M, et al. An integrative model of patient-centeredness—a systematic review and concept analysis. PLoS One 2014;9:e107829.
16. Bodenheimer T, Wagner E, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model. JAMA 2002;288:1775–9.
17. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA 2002;288:1909–14.
18. Greenhalgh T, Hurwitz B. Narrative based medicine. London: BMJ Books, 1998.
19. Charon R. Narrative medicine: honoring the stories of illness. New York: Oxford University Press, 2006.
20. Concil C. Narrative medicine and the personalisation of treatment for elderly patients. Eur J Intern Med 2016;32:22–5.
21. Wilson A, Childs S. The relationship between consultation length, process and outcomes in general practice: a systematic review. Br J Gen Pract 2002;52:1012–20.
22. Moen J, Bohm A, Tilleinus T, et al. ‘I don’t know how many of these [medicines] are necessary’—a focus group study among elderly users of multiple medicines. Patient Educ Couns 2009;74:135–41.
23. Green JL, Hawley JN, Rask KJ. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmacother 2007;5:31–9.
24. Spinewine A, Schmader KE, Barber N, et al. Appropriately prescribing in elderly people: how well can it be measured and optimised? Lancet 2007;370:173–84.
25. Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. J Am Geriatr Soc 2009;57:560–1.
26. Kaduszkiewicz H, Streich W, Fuchs A, et al. Kann die hausärztliche Versorgung multimorbider Patienten in Deutschland mit Hilfe des Chronic-Care-Modells verbessert werden? Ergebnisse der Pilotierung der clusterrandomisierten, kontrollierten Interventionssstudie MultiCare 4. [Article in German]. Z Gerontol Geriat Gerontol 2011;44(Suppl 2):95–8.
27. Schäfer I, Hansen H, Schön G, et al. The German multicare-study: patterns of multimorbidity in primary health care—protocol of a prospective cohort study. BMC Health Serv Res 2009;9:145.
28. Altiner A, Schäfer I, Mellert C, et al. Activating GENeral practitioners dialogue with patients on their Agenda (MultiCare AGENDA) study protocol for a cluster randomized controlled trial. BMC Fam Pract 2012;13:118.
29. Barrows HS. Simulated patients in medical teaching. Can Med Assoc J 1968;98:674–6.
30. Curtis JR, Back AL, Ford OW, et al. Effect of communication skills training for residents and nurse practitioners on quality of communication with patients with serious illness: a randomized trial. JAMA 2013;310:2271–81.
31. Steinman MA, Hanlon JT. Managing medications in clinically complex elders: ’There’s got to be a happy medium’ JAMA 2010;304:1592–601.
32. Brauns H, Steinmann S. Educational reform in France, West-Germany and the United Kingdom: updating the CASMIN educational classification. ZUMA-Nachrichten 1999;44:7–74.
33. Wensing M, Baker R, Vedsted P, et al; Europeop 2006. Revised EUROPEP instrument and user manual. Nijmegen: UMC St. Radboud, 2006.
34. Gagnon M, Hibert R, Dubé M, et al. Development and validation of an instrument measuring individual empowerment in relation to personal health care: the Health Care Empowerment Questionnaire (HCEQ). Am J Health Promot 2006;20:349–55.
35. Luppa M, Heinrich S, Matschinger H, et al. Direct costs associated with mild cognitive impairment in primary care. Int J Geriatr Psychiatry 2008;23:963–71.
36. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol 1986;5:165–73.
37. Jaccard P. Nouvelles recherches sur la distribution florale. Bull Soc Vaud Sci Nat 1908;44:223–70.
38. EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.
39. Szende A, Oppe M, Devlin N. EQ-5D value sets. Inventory, comparative review and user guide. Berlin: Springer Netherlands, 2007.
40. Schäfer I, Hansen H, Schön G, et al. The influence of age, gender and socio-economic status on multimorbidity patterns in primary care. First results from the multicare cohort study. BMC Health Serv Res 2012;12:89.
41. Victor A, Elsaßner A, Hommel G, et al. Wie bewertet man die $\text{p}$-Wert-Flut? Hinweise zum Umgang mit dem multiplen Testen [Article in German]. Dtsch Ärzteblatt Int 2010;107:50–6.
42. Zhang J, Yu KF, KF Y. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:1690–1.
43. Löfler C, Kaduszkiewicz H, Stolzenbach CO, et al. Coping with multimorbidity in old age—a qualitative study. BMC Fam Pract 2012;13:45.
44. Löffler C, Altiner A, Streich W, et al. [Approaches of general practitioners and patients to multimorbidity. Qualitative study]. Z Gerontol Geriatr 2015;48:452–6.
45. Reeve E, To J, Hendrix I, et al. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging 2015;33:783–807.
46. Anderson K, Stowasser D, Freeman C, et al. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open 2014;4:e006544.
47. Sengstaken EA, King SA. The problems of pain and its detection among geriatric nursing home residents. J Am Geriatr Soc 1993;41:541–4.
48. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007;5:345–51.
49. Fillenbaum GG, Horner RD, Hanlon JT, et al. Factors predicting change in prescription and nonprescription drug use in a community-residing black and white elderly population. J Clin Epidemiol 1996;49:587–93.
50. Jörgensen T, Johansson S, Kennerfalk A, et al. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 2001;35:1004–9.
51. Gnjidic D, Le Couteur DG, Kouladjian L, et al. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med 2012;28:237–53.
52. Tamura BK, Bell CL, Lubimir K, et al. Physician intervention for medication reduction in a nursing home: the polypharmacy outcomes project. J Am Med Dir Assoc 2011;12:326–30.
53. Page AT, Clifford RM, Potter K, et al. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol 2016;82:532–48.